Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Acute effect of rosiglitazone on relaxation responses in hypercholesterolemic corpus cavernosum

International Journal of Impotence Research volume 28, pages 110–113 (2016)Cite this article

Subjects

Abstract

Thiazolidinediones (TZDs) improve vascular endothelial dysfunction through non-genomic effects of peroxisomal proliferator-activated receptor γ. This study investigated the acute effect of one of the TZD, rosiglitazone, on endothelium-dependent relaxation response of corpus cavernosum (CC) in hypercholesterolemic rabbits. New Zealand rabbits were divided into two groups randomly as control and cholesterol groups. Hypercholesterolemia was induced by feeding rabbits with 2% cholesterol diet (w/w) for 6 weeks. Endothelium-dependent and -independent relaxation response of CC were evaluated in the presence of rosiglitazone by organ bath studies with cumulative doses of acetylcholine (Ach) and sodium nitroprusside (SNP). Maximal relaxation (Emax) response to Ach significantly decreased owing to hypercholesterolemia in CC tissues. However, in vitro incubation of rosiglitazone with different concentrations (0.1, 1 and 10 μm) did not improve the Ach-dependent Emax responses in hypercholesterolemic rabbit CC. Surprisingly, rosiglitazone caused a significant decrease in Ach-dependent relaxation in healthy CC. Emax responses to SNP did not differ in the presence of rosiglitazone in both the control and hypercholesterolemic groups. Rosiglitazone does not improve hypercholesterolemia-induced endothelial dysfunction in CC tissues while it dose-dependently impairs endothelium-dependent relaxation in healthy CC tissue.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Bivalacqua TJ, Usta MF, Champion HC, Kadowitz PJ, Hellstrom WJG . Endothelial dysfunction in erectile dysfunction: role of the endothelium in erectile physiology and disease. J Androl 2003; 24: S17–S37.

    Article  CAS  Google Scholar 

  2. Castela A, Vendeira P, Costa C . Testosterone, endothelial health, and erectile function. ISRN Endocrinol 2011; 2011: 839149.

    Article  Google Scholar 

  3. Xie D, Annex BH, Donatucci CF . Growth factors for therapeutic angiogenesis in hypercholesterolemic erectile dysfunction. Asian J Androl 2008; 10: 23–27.

    Article  CAS  Google Scholar 

  4. Fraga-Silva RA, Costa-Fraga FP, Faye Y, Sturny M, Santos RA, da Silva RF et al. An increased arginase activity is associated with corpus cavernosum impairment induced by hypercholesterolemia. J Sex Med 2014; 11: 1173–1181.

    Article  CAS  Google Scholar 

  5. Liu H-R, Tao L, Gao E, Qu Y, Lau WB, Lopez BL et al. Rosiglitazone inhibits hypercholesterolaemia-induced myeloperoxidase upregulation—a novel mechanism for the cardioprotective effects of PPAR agonists. Cardiovasc Res 2009; 81: 344–352.

    Article  CAS  Google Scholar 

  6. Tao L, Liu H-R, Gao E, Teng Z-P, Lopez BL, Christopher TA et al. Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator–activated receptor-γ agonist in hypercholesterolemia. Circulation 2003; 108: 2805–2811.

    Article  CAS  Google Scholar 

  7. Berger JP, Akiyama TE, Meinke PT . PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci 2005; 26: 244–251.

    Article  CAS  Google Scholar 

  8. Mather KJ . The vascular endothelium in diabetes—a therapeutic target? Rev Endocr Metab Disord 2013; 14: 87–99.

    Article  CAS  Google Scholar 

  9. Gholamine B, Shafiei M, Motevallian M, Mahmoudian M . Effects of pioglitazone on erectile dysfunction in sildenafil poor-responders: a randomized, controlled study. J Pharm Pharmaceut Sci 2008; 11: 22–31.

    Article  CAS  Google Scholar 

  10. Elcioglu HK, Kabasakal L, Ozkan N, Celikel C, Ayanoglu-Dulger G . A study comparing the effects of rosiglitazone and/or insulin treatments on streptozotocin induced diabetic (type I diabetes) rat aorta and cavernous tissues. Eur J Pharmacol 2011; 660: 476–484.

    Article  CAS  Google Scholar 

  11. Soner BC, Murat N, Demir O, Guven H, Esen A, Gidener S . Evaluation of vascular smooth muscle and corpus cavernosum on hypercholesterolemia. Is resveratrol promising on erectile dysfunction[quest]. Int J Impot Res 2010; 22: 227–233.

    Article  CAS  Google Scholar 

  12. Mendizabal Y, Llorens S, Nava E . Effects of pioglitazone and rosiglitazone on vascular function of mesenteric resistance arteries in rat genetic hypertension. Pharmacology 2011; 88: 72–81.

    Article  CAS  Google Scholar 

  13. Bivalacqua TJ, Usta MF, Champion HC, Kadowitz PJ, Hellstrom WJ . Endothelial dysfunction in erectile dysfunction: role of the endothelium in erectile physiology and disease. J Androl 2003; 24: S17–S37.

    Article  CAS  Google Scholar 

  14. Shukla N, Jones R, Persad R, Angelini GD, Jeremy JY . Effect of sildenafil citrate and a nitric oxide donating sildenafil derivative, NCX 911, on cavernosal relaxation and superoxide formation in hypercholesterolaemic rabbits. Eur J Pharmacol 2005; 517: 224–231.

    Article  CAS  Google Scholar 

  15. Behr-Roussel D, Bernabe J, Compagnie S, Rupin A, Verbeuren TJ, Alexandre L et al. Distinct mechanisms implicated in atherosclerosis-induced erectile dysfunction in rabbits. Atherosclerosis 2002; 162: 355–362.

    Article  CAS  Google Scholar 

  16. Burnett AL, Musicki B, Jin L, Bivalacqua TJ . Nitric oxide/redox-based signalling as a therapeutic target for penile disorders. Expert Opin Ther Targets 2006; 10: 445–457.

    Article  CAS  Google Scholar 

  17. Yki-Jarvinen H . Thiazolidinediones. N Engl J Med 2004; 351: 1106–1118.

    Article  Google Scholar 

  18. Kovanecz I, Ferrini MG, Vernet D, Nolazco G, Rajfer J, Gonzalez-Cadavid NF . Ageing-related corpora veno-occlusive dysfunction in the rat is ameliorated by pioglitazone. BJU Int 2007; 100: 867–874.

    Article  CAS  Google Scholar 

  19. Gurnell M . PPARgamma and metabolism: insights from the study of human genetic variants. Clin Endocrinol 2003; 59: 267–277.

    Article  CAS  Google Scholar 

  20. Aliperti LA, Lasker GF, Hagan SS, Hellstrom JA, Gokce A, Trost LW et al. Efficacy of pioglitazone on erectile function recovery in a rat model of cavernous nerve injury. Urology 2014; 84: 1122–1127.

    Article  Google Scholar 

  21. Aliperti LA, Hellstrom WJ . Pioglitazone prevents cavernosal nerve injury after radical prostatectomy. Med Hypotheses 2014; 82: 504.

    Article  CAS  Google Scholar 

  22. Kovanecz I, Ferrini MG, Vernet D, Nolazco G, Rajfer J, Gonzalez-Cadavid NF . Pioglitazone prevents corporal veno-occlusive dysfunction in a rat model of type 2 diabetes mellitus. BJU Int 2006; 98: 116–124.

    Article  CAS  Google Scholar 

  23. Ryan MJ, Didion SP, Mathur S, Faraci FM, Sigmund CD . PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension 2004; 43: 661–666.

    Article  CAS  Google Scholar 

  24. Tao L, Liu HR, Gao E, Teng ZP, Lopez BL, Christopher TA et al. Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia. Circulation 2003; 108: 2805–2811.

    Article  CAS  Google Scholar 

  25. Zhao Z, Luo Z, Wang P, Sun J, Yu H, Cao T et al. Rosiglitazone restores endothelial dysfunction in a rat model of metabolic syndrome through PPARgamma- and PPARdelta-dependent phosphorylation of Akt and eNOS. PPAR Res 2011; 2011: 291656.

    Article  Google Scholar 

  26. Yang XH, Li P, Yin YL, Tu JH, Dai W, Liu LY et al. Rosiglitazone via PPARgamma-dependent suppression of oxidative stress attenuates endothelial dysfunction in rats fed homocysteine thiolactone. J Cell Mol Med 2015; 19: 826–835.

    Article  CAS  Google Scholar 

  27. Majithiya JB, Paramar AN, Balaraman R . Pioglitazone, a PPARgamma agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats. Cardiovasc Res 2005; 66: 150–161.

    Article  CAS  Google Scholar 

  28. Llorens S, Mendizabal Y, Nava E . Effects of pioglitazone and rosiglitazone on aortic vascular function in rat genetic hypertension. Eur J Pharmacol 2007; 575: 105–112.

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. H Akdag and N Murat: HA and NDM contributed equally to this work.

Authors and Affiliations

  1. Department of Pharmacology, Faculty of Medicine, University of Dokuz Eylul, Balcova, Izmir, Turkey

    H Akdag, N Murat, S Evcim & S Gidener

  2. Department of Urology, Faculty of Medicine, University of Dokuz Eylul, Balcova, Izmir, Turkey

    A Esen

Authors
  1. H Akdag
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N Murat
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Evcim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Esen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Gidener
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N Murat.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Akdag, H., Murat, N., Evcim, S. et al. Acute effect of rosiglitazone on relaxation responses in hypercholesterolemic corpus cavernosum. Int J Impot Res 28, 110–113 (2016). https://doi.org/10.1038/ijir.2016.11

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ijir.2016.11

Search

Advanced search

Quick links